Gynuity Health Projects


Mifepristone label laws and trends in use: recent experiences in four US states

Since mifepristone was approved in 2000, the rate of medical abortions has risen fairly steadily from just 6% of all eligible abortions in 2001 to 29% in 2011. If unconstrained access to medical abortions were the norm, rather than the exception, medical abortions might constitute a higher percentage of all abortions. Furthermore, the on-label use of mifepristone involves use of an outdated regimen of 600 mg that is more expensive and arguably less effective, with greater side effects than the evidence-based regimen of 200 mg that is currently the world-wide standard of care. In order to examine further the possible effect of mifepristone-specific restrictions, researchers documented trends in mifepristone use over a 10-year period (2004–2014) in four large US states: California, New York, Ohio and Texas.

Access the full text.